Literature DB >> 27376733

Relationship Between Noncoding RNA Dysregulation and Epigenetic Mechanisms in Cancer.

Hiromu Suzuki1, Reo Maruyama2, Eiichiro Yamamoto2,3, Takeshi Niinuma2, Masahiro Kai2.   

Abstract

Epigenetic alterations, including aberrant DNA methylation and histone modification, play key roles in the dysregulation of tumor-related genes, thereby affecting numerous cellular processes, including cell proliferation, cell adhesion, apoptosis, and metastasis. In recent years, studies have demonstrated that short and long noncoding RNAs (ncRNAs) are key players in the initiation and progression of cancer, and epigenetic mechanisms are deeply involved in their dysregulation. Indeed, the growing list of microRNA (miRNA) genes aberrantly methylated in cancer suggests that a large number of miRNAs act as tumor suppressors or oncogenes. In addition, emerging evidence suggests that dysregulation of long ncRNAs (lncRNAs) plays critical roles in tumorigenesis. And because ncRNAs are involved in regulating gene expression through interaction with epigenetic modifiers, their dysregulation appears causally related to epigenetic alterations in cancer. Dissection of the interrelationships between ncRNAs and epigenetic alterations has the potential to reveal novel approaches to the diagnosis and treatment of cancer.

Entities:  

Keywords:  Epigenetic mechanism; RNA dysregulation; Tumor-related genes; ncRNA

Mesh:

Substances:

Year:  2016        PMID: 27376733     DOI: 10.1007/978-981-10-1498-7_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

Review 1.  Reciprocal regulations between miRNAs and HIF-1α in human cancers.

Authors:  Wanli Yang; Jiaojiao Ma; Wei Zhou; Bo Cao; Xin Zhou; Hongwei Zhang; Qingchuan Zhao; Liu Hong; Daiming Fan
Journal:  Cell Mol Life Sci       Date:  2018-10-13       Impact factor: 9.261

2.  The DNA methylation profile of non-coding RNAs improves prognosis prediction for pancreatic adenocarcinoma.

Authors:  Jie Zhang; Keqing Shi; Weiguo Huang; Wanqing Weng; Zhongjing Zhang; Yangyang Guo; Tuo Deng; Yukai Xiang; Xiaofeng Ni; Bicheng Chen; Mengtao Zhou
Journal:  Cancer Cell Int       Date:  2019-04-23       Impact factor: 5.722

3.  HOTAIR Long Non-coding RNA: Characterizing the Locus Features by the In Silico Approaches.

Authors:  Mohammadreza Hajjari; Saghar Rahnama
Journal:  Genomics Inform       Date:  2017-12-29

Review 4.  Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs.

Authors:  Damiano Bartolucci; Andrea Pession; Patrizia Hrelia; Roberto Tonelli
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525

5.  Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATβ axis.

Authors:  Zehua Zhang; Qiang Zhou; Fei Luo; Rui Zhou; Jianzhong Xu; Jun Xiao; Fei Dai; Lei Song
Journal:  Hum Cell       Date:  2021-06-23       Impact factor: 4.174

Review 6.  Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.

Authors:  Yixiao Feng; Mia Spezia; Shifeng Huang; Chengfu Yuan; Zongyue Zeng; Linghuan Zhang; Xiaojuan Ji; Wei Liu; Bo Huang; Wenping Luo; Bo Liu; Yan Lei; Scott Du; Akhila Vuppalapati; Hue H Luu; Rex C Haydon; Tong-Chuan He; Guosheng Ren
Journal:  Genes Dis       Date:  2018-05-12

Review 7.  Regulation of Thermogenic Adipocyte Differentiation and Adaptive Thermogenesis Through Histone Acetylation.

Authors:  Belinda X Ong; Reinhard Brunmeir; Qiongyi Zhang; Xu Peng; Muhammad Idris; Chungang Liu; Feng Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-27       Impact factor: 5.555

8.  Integrative bioinformatics analysis identifies LINC01614 as a potential prognostic signature in esophageal cancer.

Authors:  Shuo Yan; Jichong Xu; Bingyan Liu; Lin Ma; Huaqiao Tan; Chun Fang
Journal:  Transl Cancer Res       Date:  2021-04       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.